A clinical study on efficacy of gemcitabine and carboplatin versus paclitaxel and carboplatin in the treatment of advanced non-small-cell lung cancer

Abstract

目的 观察吉西他滨(GEM)加卡铂(CBP)与紫杉醇(TAX)加卡铂治疗晚期非小细胞肺癌的疗效及毒副反应.方法 将经病理组织学或细胞学证实的64例晚期非小细胞肺癌患者,随机分为GC组30例和TC组34例,分别给予GEM+CBP及TAX+CBP治疗,28天为一个周期,均治疗2周期以上.结果 GC组总有效率为53.3%,TC组总有效率为58.8%(P＞0.05).毒副反应以白细胞降低、胃肠道反应和周围神经炎为主,TC组的发生率显著高于GC组(P＜0.05),但均可耐受.结论 吉西他滨加卡铂与紫杉醇加卡铂治疗晚期非小细胞肺癌均有较好的近期疗效,患者耐受性好,而吉西他滨组的毒副反应更轻,临床应用更安全.

Objective To evaluate the efficacy and toxicity of gemcitabine and carboplatin (GC) versus paclitaxel and carboplatin (TC) in the treatment of non-small cell lung cancer (NSCLC). Methods A total of 64 patients with advanced NSCLC diagnosed by pathology were randomly divided into two groups. Gemcitabine and carboplatin were administrated to the patients in GC group (n=30), and paclitaxel and carboplatin in the TC group (n=34), 28 days as a cycle. All patients received at least two cycles. Results The overall response rate was 53.3% in the GC group and 58.8% in the TC group (P > 0.05). The main toxicities were well tolerated and consisted of leukopenia, nausea, vomiting and peripheral neuritis, which occurred more frequently in the TC group than in the GC group (P < 0.05). Conclusion Both of the two regimens of gemcitabine plus carboplatin and paclitaxel plus carboplatin are feasible, well tolerated and effective in the treatment of NSCLC, and the former may be safer than the latter.